| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $525K | — | +66.9% |
| SG&A Expense | $579K | — | -61.2% |
| Net Income | -$1.2M | — | +35.5% |
| EPS (Basic) | -$0.03 | — | +72.7% |
| EPS (Diluted) | -$0.03 | — | +72.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $4.8M | -24.1% | +299.2% |
| Short-term Investments | $4.6M | -2.0% | — |
| Current Assets | $9.4M | -14.7% | +590.8% |
| Total Assets | $9.5M | -14.7% | +575.8% |
| Current Liabilities | $115K | -83.7% | +8.1% |
| Total Liabilities | $115K | -83.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.2M | — | +26.3% |
| Financing Cash Flow | -$331K | — | -9878.4% |
| +8.1% |
| Stockholders' Equity | $9.3M | -10.0% | +622.4% |